XCELLIT

Live / Registered — Registered (as of 27 Feb 2024)

What this means for you

Registered since 27 Feb 2024. The owner can stop confusingly similar uses in the classes it covers.

Record

Serial number
97664408
Registration number
7313860
Mark type
Word mark
Filed
05 Nov 2022
Published for opposition
12 Dec 2023
Registered
27 Feb 2024
Attorney of record
Alexandra MacKay

Goods and services

  • Class 009 — Scientific and electric apparatus: recorded software used as medical monitoring and control tool, specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and coordinates scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information; recorded software as a medical device (SaMD), specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and coordinates scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information; recorded computer software for use in medical decision support systems specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and coordinates scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information, and that supports clinical decisions regarding the use of blood derived cells for infusion and treatment and the analysis of the results from such treatment
  • Class 010 — Medical apparatus: Medical apparatus and instruments for use in apheresis, production of cell and gene therapies, testing, analysis, and quality assurance of cell and gene therapies, infusion of cell and gene therapies, and analysis of data gathered from the cell and gene therapy treatment; apparatus and instruments for cell analysis for medical use, namely, cancer and autoimmune disease treatment; medical apparatus in the nature of a system comprising an automated manufacturing device, reagents, software for the purpose of coordinating the treatment of patients, monitoring and conducting quality control on the testing of blood derived cells, supporting clinical decisions regarding the use of such cells for infusion and treatment, and the analysis of the results from such treatment
  • Class 042 — Scientific and technological services: Software as a service (SAAS) services featuring software for medical monitoring and control specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information; providing temporary use of nondownloadable, cloud-based software featuring software for medical monitoring and control specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and coordinates scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information; software as a service (SAAS) services for use in medical decision support systems, specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and coordinates scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information, and that supports clinical decisions regarding the use of blood derived cells for infusion and treatment and the analysis of the results from such treatment; providing temporary use of non-downloadable, cloud-based software featuring software for use in medical decision support systems, specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and coordinates scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information, and that supports clinical decisions regarding the use of blood derived cells for infusion and treatment and the analysis of the results from such treatment; Providing information about the results of clinical trials for pharmaceutical products; scientific research in the nature of conducting clinical trials; Providing information about the results of clinical trials; evaluation pharmaceutical products in the nature of product quality testing; providing information regarding the product quality testing and clinical trials of pharmaceutical products; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; medical and pharmaceutical product quality testing; advisory and consultancy services in the field of medical and pharmaceutical product development
  • Class 044 — Medical, beauty and agricultural services: Medical services; medical and pharmaceutical evaluation of medical and pharmaceutical products to determine effectiveness and suitability for use in treatment of specific medical conditions; medical services, namely, cell therapy services; Medical services relating to the removal, treatment and processing of human cells

Owner

Prosecution history

  • 27 Feb 2024 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
  • 27 Feb 2024 — REGISTERED-PRINCIPAL REGISTER
  • 12 Dec 2023 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
  • 12 Dec 2023 — PUBLISHED FOR OPPOSITION
  • 22 Nov 2023 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
  • 06 Nov 2023 — APPROVED FOR PUB - PRINCIPAL REGISTER
  • 06 Nov 2023 — ASSIGNED TO EXAMINER
  • 18 Sept 2023 — TEAS/EMAIL CORRESPONDENCE ENTERED
  • 18 Sept 2023 — CORRESPONDENCE RECEIVED IN LAW OFFICE
  • 17 Sept 2023 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
  • 24 Aug 2023 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
  • 24 Aug 2023 — NON-FINAL ACTION E-MAILED
  • 24 Aug 2023 — NON-FINAL ACTION WRITTEN
  • 21 Aug 2023 — ASSIGNED TO EXAMINER
  • 19 Jan 2023 — PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED

View this trademark record on Marksy